<DOC>
	<DOCNO>NCT02574637</DOCNO>
	<brief_summary>A Phase 2b study evaluate efficacy safety MEDI2070 Subjects Moderate Severe Crohn 's Disease Who Have Failed Are Intolerant Anti Tumor Necrosis Factor-Alpha Therapy</brief_summary>
	<brief_title>Evaluation Efficacy Safety MEDI2070 Subjects With Active , Moderate Severe Crohn 's Disease</brief_title>
	<detailed_description>This four-part Phase 2b study comprise 16-week , double-blind , placebo-controlled , Induction Period , 12-week double-blind , placebo-controlled , Maintenance Period , 24-week , Open-label Period post-treatment 28 week observational safety follow-up period design evaluate short-term efficacy short- long term safety MEDI2070 subject moderate severe , active CD fail intolerant anti-TNFα therapy determine Investigator .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Diagnosis ileal , ileocolonic , colonic Crohn 's Disease ( CD ) &gt; 3 month prior screen Men woman age 18 80 year time screen Moderate severely active CD , define Crohn 's Disease Activity Index ( CDAI ) AND endoscopic demonstration inflammation Stable dose medication Crohn 's disease therapy Prior treatment failure intolerance least one Anti Tumor Necrosis FactorAlpha Therapy ( antiTNF α ) agent . Effective contraception screening , 36 week last dose investigational product No known history active tuberculosis ( TB ) &amp; negative assessment TB/latent TB Severe underlie immunosuppression Severe gastrointestinal complication ; e.g. , short bowel syndrome , obstruct stricture , recent plan bowel surgery , Ileostomy and/or colostomy , recent bowel perforation Significant infection screen ; Infected abscess , positive Clostridium difficile , recent infectious hospitalization , Recent treatment approve investigational biologic therapy Crohn 's disease Recent plan live attenuated vaccine History cancer , except basal cell carcinoma CIS cervix apparent cure ≥ 12 month screen Pregnancy/breast feeding Drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>MEDI2070</keyword>
	<keyword>inflammatory bowel disease</keyword>
	<keyword>moderate severe Crohn 's Disease</keyword>
	<keyword>IL-23</keyword>
</DOC>